FDA briefing documents released Friday morning in advance of Tuesday's Arthritis Advisory Committee Meeting suggested the agency will go gentle on the biologics license application for CT-P13, Celltrion Inc.'s biosimilar to Remicade (infliximab, Janssen Biotech Inc.) that is approved elsewhere as Remsima (infliximab). .